Development of Enzyme Linked Immunosorbent Assay for humoral immuneresponse and infection monitoring of anthrax

PDF (English)
DOI: https://doi.org/10.12681/jhvms.22964
H. R. NOURI
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
H. RAZZAZ
Student Research Committee, Babol University of Medical Sciences, Babol, Iran Department of Immunology, Razi Vaccine & Serum Research Institute, Agricultural Research, Education & Extension Organization (AREEO), Karaj, Iran
M. TAGHDIRI
Department of Immunology, Razi Vaccine & Serum Research Institute, Agricultural Research, Education & Extension Organization (AREEO), Karaj, Iran
K. TADAYON
Department of Veterinary Aerobic Bacteria, Razi Vaccine & Serum Research Institute, Agricultural Research, Education & Extension Organization (AREEO), Karaj, Iran
S. R. BANIHASHEMI
Department of Immunology, Razi Vaccine & Serum Research Institute, Agricultural Research, Education & Extension Organization (AREEO), Karaj, Iran
Аннотация

Immune assays were taken into consideration to diagnose and quantify metabolites such as antigen and antibody. Enzyme-Linked Immunosorbent Assays (ELISAs), which are used to detect antigens and antibodies, generated several periods of infectious and vaccination conditions. There is an extensive range of commercial infectious disease ELISA kits useful for the detection of human and animal IgG, IgA, IgM antibodies and microorganism antigens. Anthrax is one of the serious infectious diseases caused by rod-shaped, gram-positive bacteria known as Bacillus anthracis. Subunit or attenuated vaccines applied against anthrax disease increase the antibody against the Protective Antigen (PA) which has a critical role as a toxin of B. anthracis. Herein, the ELISA was developed using PA domain 4 and anthrax Lethal Factor to detect IgG antibody in serum. Besides, the level of anti-LF antibodies were determined as a complementary test to measure variance in antibody titers associated with vaccination or infection that leads to detection of anthrax in livestock. The results show that we developed high-quality ELISA kit that can be used to test immunogenicity of vaccines and infections in mice. We tried to develop the Anti- PA4 ELISA kit and conduct the validation studies to evaluate the fluctuation level of the antibody in the anthrax vaccine and distinction between disease and vaccination in mice.

Article Details
  • Раздел
  • Research Articles
Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial» («Атрибуция — Некоммерческое использование») 4.0 Всемирная.

Authors who publish with this journal agree to the following terms:

· Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

· Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g. post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

· Authors are permitted and encouraged to post their work online (preferably in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Скачивания
Данные скачивания пока недоступны.
Библиографические ссылки
Baillie LW, Huwar TB, Moore S, Mellado-Sanchez G, Rodriguez L, Neeson BN, et al.(2010). An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.Vaccine,28(41):6740-8.doi: 10.1016/j.vaccine.2010.07.075. [PubMed: 20691267].
Chen L, Schiffer JM, Dalton S, Sabourin CL, Niemuth NA, Plikaytis BD, et al.(2014). Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques. Clinical and Vaccine Immunology,21(11):1512-20.doi: 10.1128/CVI.00469-14.[PubMed:25185557].
Caldwell M, Hathcock T, Brock K.(2017). Validation of an Anti-Protective Antigen ELISA for Quantitative IgG Evaluation in B. anthracis Immunized Horses. J Vet Sci Ani Husb,5(3):304.
Dumas EK, Gross T, Larabee J, Pate L, Cuthbertson H, Charlton S, et al.(2017). Anthrax Vaccine Precipitated induces Edema Toxin-neutralizing, Edema Factor-specific antibodies in human recipients. Clinical and Vaccine Immunology,24(11):e00165-17. doi: 10.1128/CVI.00165-17. [pubmed: 28877928].
Dumas EK, Garman L, Cuthbertson H, Charlton S, Hallis B, Engler RJ, et al.(2017). Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated. Vaccine, 35(26):3416-22. doi: 10.1016/j.vaccine.2017.05.006.[pubmed:28504191].
Flick-Smith HC, Walker NJ, Gibson P, Bullifent H, Hayward S, Miller J, et al.(2002). A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infection and immunity ,70(3):1653-6.doi: 10.1128/IAI.70.3.1653-1656.2002. [PubMed: 11854261].
Ghosh N, Gunti D, Lukka H, Reddy B, Padmaja J, Goel A.(2015). Development & validation of a quantitative anti-protective antigen IgG enzyme linked immunosorbent assay for serodiagnosis of cutaneous anthrax. The Indian Journal of Medical Research ,142(2):196.doi:10.4103/0971-5916.164258.[PubMed:26354217].
Goldstein JM, Lee J, Tang X, Boyer AE, Barr JR, Bagarozzi Jr DA, et al.(2017). Phage Display Analysis of Monoclonal Antibody Binding to Anthrax Toxin Lethal Factor. Toxins,9(7):221. doi: 10.3390/toxins9070221.
Head BM, Rubinstein E, Meyers AF.(2016). Alternative pre-approved and novel therapies for the treatment of anthrax. BMC infectious diseases, 16(1):621. doi: 10.1186/s12879-016-1951-y. [pubmed: 27809794].
Ionin B, Hopkins RJ, Pleune B, Sivko GS, Reid FM, Clement KH, et al.(2013). Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Clinical and Vaccine Immunology,20(7):1016-26. doi: 10.1128/CVI.00099-13.[pubmed:23658392].
Ingram RJ, Metan G, Maillere B, Doganay M, Ozkul Y, Kim LU, et al.(2010). Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes. The Journal of Immunology,184(7):3814-2.doi:10.4049/jimmunol.09015811.[PubMed: 20208010].
Laws TR, Kuchuloria T, Chitadze N, Little SF, Webster WM, Debes AK, et al.(2016). A comparison of the adaptive immune response between recovered anthrax patients and individuals receiving three different anthrax vaccines. PloS one. 11(3):e0148713, doi: 10.1371/journal. pone.0148713.[pubmed: 27007118].
MOAZENI JGR, JABARI A.(2007). Stability and potency studies of anthrax vaccine (Bacillus anthracis 34F2 Sterne strain) in Iran.. Archives of Razi Institute,62(3):145-149.
Miller MJ, Astles R, Baszler T, Chapin K, Carey R, Garcia L, et al.(2012). Guidelines for safe work practices in human and animal medical diagnostic laboratories. MMWR Surveill Summ,6(61):1-102.[pubmed: 22217667].
Mitic K, Muhandes L, Minic R, Petrusic V, Zivkovic I.(2016). Optimization and Validation of ELISA for Pre-Clinical Trials of Influenza Vaccine. Folia Biologica(Praha),62:241-9.[PubMed: 28189147].
Male AL, Forafonov F, Cuda F, Zhang G, Zheng S, Oyston PC, et al.(2017). Targeting Bacillus anthracis toxicity with a genetically selected inhibitor of the PA/CMG2 protein-protein interaction. Scientific reports,7(1):3104. doi: 10.1038/s41598-017-03253-3.[pubmed: 28596569].
Mamillapalli S, Miyagi M, Bann JG.(2017). Stability of domain 4 of the anthrax toxin protective antigen and the effect of the VWA domain of CMG2 on stability. Protein Science,26(2):355-64. doi: 10.1002/pro.3087.[pubmed: 27874231].
Malik A, Gupta M, Mani R, Gogoi H, Bhatnagar R.(2018). Trimethyl chitosan nanoparticles encapsulated Protective antigen Protects the Mice against anthrax. Frontiers in immunology,9:562. doi: 10.3389/fimmu.2018.00562.[pubmed: 26616046].
Ndumnego OC, Crafford J, Beyer W, Van Heerden H.(2013). Quantitative anti-PA IgG ELISA; assessment and comparability with the anthrax toxin neutralization assay in goats. BMC veterinary research,9(1):265.doi: 10.1186/1746-6148-9-265.[PubMed: 24373579].
Pombo M, Berthold I, Gingrich E, Jaramillo M, Leef M, Sirota L, et al.(2004). Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice. Biologicals,32(3):157-63.doi:10.1016/j.biologicals. 2004.03.002. [PubMed: 15536047].
Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, et al.(2001). Search for correlates of protective immunity conferred by anthrax vaccine. Infection and immunity,69(5):2888-93.doi: 10.1128/IAI.69.5.2888-2893.2001. [PubMed: 11292703].
Semenova V, Schiffer J, Steward-Clark E, Soroka S, Schmidt D, Brawner M, et al.(2012). Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG. Journal of immunological meth ods,376(1-2):97-107.doi:10.1016/j.jim.2011.12.002. [PubMed:22197974].
Semenova VA, Steward-Clark E, Maniatis P, Epperson M, Sabnis A, Schiffer J.(2017). Validation of high throughput screening of human sera for detection of anti-PA IgG by Enzyme-Linked Immunosorbent Assay (ELISA) as an emergency response to an anthrax incident. Biologicals. ,45:61-8.doi:10.1016/j.biologicals.2016.09.012. [PubMed:27814939 ].
Sim BKL, Li M, Osorio M, Wu Y, Wai TT, Peterson JW, et al.(2017). Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis. NPJ vaccines,2(1):17. doi: 10.1038/s41541-017-0018-4.[pubmed: 29263873].
Tadayon K, Moazeni Jula G, Banihashemi R, Sekhavati M, Naseri Rad A, Razaz H.(2016). A Study on molecular characterization of Razi Bacillus anthracis Sterne 34F2 substrain in Iran. Archives of Razi Institute, 71(2):81-86. doi:10.22034/ari.2016.106445.
Weiss MM, Weiss PD, Weiss JB.(2007). Anthrax vaccine and public health policy.American journal of public health ,97(11):1945-51. DOI: 10.2105/AJPH.2006.102749. [PubMed: 17901434].
Williamson D, Dyson EH.(2015). Anthrax prophylaxis: recent advances and future directions. Frontiers in microbiology ,6:1009. doi: 10.3389/fmicb.2015.01009.[pubmed: 26441934].
Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC.(1994). Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology ,199: 132-40.
Zai X, Zhang J, Liu J, Liu J, Li L, Yin Y, et al.(2016). Quantitative determination of lethal toxin proteins in culture supernatant of human live anthrax vaccine bacillus anthracis A16R. Toxins,8(3):56. doi:10.3390/toxins8030056.[pubmed]